<DOC>
	<DOCNO>NCT01560572</DOCNO>
	<brief_summary>A prospective , open , randomized trial , investigator aim achieve optimal immunosuppression renal renal transplantation maximal reduction side effect , especially vascular injury , chronic allograft nephropathy , osteoporosis malignancy . Immunosuppression without steroid CNI minimization compare standard immunosuppression , consist tacrolimus OD , mycophenolic acid corticosteroid .</brief_summary>
	<brief_title>Steroid Free Immunosuppression Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy Kidney Transplantation : Comparison With Standard Quadruple Immunosuppressive Regimen</brief_title>
	<detailed_description>Before transplantation 300 patient randomize 1:1:1 three group . Group 1 treat basiliximab induction three day course steroid follow steroid free maintenance regimen consist standard-dose tacrolimus OD mycophenolic acid . Group 2 treat Basiliximab induction follow standard-dose tacrolimus OD , mycophenolic acid steroid . Group 3 treat basiliximab induction follow standard-dose tacrolimus OD six month , whereafter dose reduce plus mycophenolic acid steroid . The total study period 2 year . Primary endpoint renal function , proteinuria microalbuminuria measure 6 , 12 , 24 month transplantation . Renal function measure serum Creatinine , Creatinine clearances Nankivell GFR ( 4 ) . Secondary endpoint degree tubular atrophy interstitial fibrosis degree arteriolar hyalinosis renal biopsy take 12 24 month transplantation . Biopsies evaluate accord Banff '07 Criteria Renal Allograft Biopsy Interpretation ( appendix II ) . Quantitative morphometric analysis interstitial fibrous tissue perform use digital image analysis technique . Other secondary endpoint patient graft survival , incidence allograft rejection , cardiovascular accident , pulse wave velocity , blood pressure , number antihypertensive , lipid profile , incidence malignancy , incidence infectious complication , incidence post transplant diabetes mellitus development osteoporosis .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>recipient kidney graft ( first second ) decease living ( nonHLA identical ) donor patient multiorgan transplant patient receive third fourth transplant patient &gt; 75 % ( current historic ) panel reactive antibody patient receive kidney HLA identical living donr female patient pregnant unwilling use adequate contraception study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>kidney transplantation</keyword>
	<keyword>immunosuppression</keyword>
	<keyword>steroid</keyword>
	<keyword>tacrolimus OD</keyword>
</DOC>